Mark Fladrich, an executive at AstraZeneca Plc, is set to become chief commercial officer at the Grünenthal Group from 1 September as the German family-owned company prepares to expand its portfolio of medicines for pain and inflammation. Mr Fladrich will lead the company’s global commercial organisation.
Currently he has responsibility for AstraZeneca’s commercial operations in southern and western Europe. He previously held country management positions for AstraZeneca in Australia, New Zealand and Germany. Mr Fladrich holds a Bachelor’s degree in pharmacy from the University of South Australia and a Master’s degree in business administration from the Macquarie Graduate School of Management.
Grünenthal announced the appointment on 9 May 2017.
Copyright 2017 Evernow Publishing Ltd